• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Avro­bio halts PhII study for Fab­ry dis­ease in an­oth­er set­back, shut­ter­ing lead pro­gram

4 years ago
R&D

Mul­ti­ple block­busters from Gilead, Pfiz­er, Ver­tex see (list) price hikes to start 2022

4 years ago
Pharma

Ther­a­nos founder Eliz­a­beth Holmes found guilty on four counts of de­fraud­ing in­vestors

4 years ago
People
Pharma

Covid-19 roundup: FDA au­tho­rizes Pfiz­er-BioN­Tech boost­er for 12-to-15-year-olds; Ear­ly re­sults sug­gest an­tivi­rals may ...

4 years ago
Coronavirus

2021's NDA list in­cludes some ex­tra­or­di­nary ac­com­plish­ments in year #2 of the pan­dem­ic

4 years ago
Special

Biotech pulls plans to file ac­cel­er­at­ed ap­proval af­ter FDA 'change in di­rec­tion' — shares plum­met

4 years ago
FDA+

No­vavax breaks an­oth­er pledge for its Covid-19 vac­cine. And the US is re­port­ed­ly fret­ting about glob­al goals now

4 years ago
R&D

FDA adds an­oth­er drug OK to cap a record win list for 2021

4 years ago
FDA+

Fol­low­ing in­flux of cash, Pi­ra­mal in­vests in an­oth­er In­di­an CD­MO; US inks deal with man­u­fac­tur­er of rapid Covid-19 ...

4 years ago
Manufacturing

Low-pro­file RNAi play­er lands on HKEX fol­low­ing mod­est $50M IPO

4 years ago
Financing
China

Not every­body is buy­ing it, but every­body is def­i­nite­ly talk­ing about a new Bio­gen buy­out re­port

4 years ago
R&D

A Jeff Aronin start­up qui­et­ly yanks its IPO as the biotech mar­ket ends year on a whim­per

4 years ago
People
Financing

Hit­ting a new record on drug ap­provals, the FDA of­fers a thumbs-up to an­oth­er atopic der­mati­tis con­tender

4 years ago
FDA+

Sutro strikes a $40M Chi­na deal as it looks to push ahead of a crowd­ed pack

4 years ago
Deals
China

Bridge­Bio shares go in­to melt­down mode as their lead PhI­II drug im­plodes at the fin­ish line

4 years ago
R&D

Covid-19 man­u­fac­tur­ing roundup: In­di­an man­u­fac­tur­er waives vac­cine pro­tec­tions for mi­grants; EMA gives go-ahead for ...

4 years ago
Coronavirus
Manufacturing

No­vo Hold­ings to help young Dan­ish com­pa­ny with ef­forts to pro­vide scale to start-ups

4 years ago
Manufacturing

On the heels of Tezspire ap­proval in US, Am­gen will add fill­ing line in Ire­land

4 years ago
Manufacturing

Durect out-li­cens­es anal­gesic Posimir to Irish biotech in $136M deal; Ar­cutis gets 9-fig­ure loan to push for OK for ...

4 years ago
News Briefing

Inno­gen nets $120M to ad­vance Trulic­i­ty, Ozem­pic ri­val; ven­ture in­to man­u­fac­tur­ing

4 years ago
Financing

FDA au­tho­rizes new Mer­ck Covid-19 pill de­spite sci­en­tist­s' con­cerns on its mech­a­nism of ac­tion

4 years ago
FDA+
Coronavirus

Ar­row­head adds newest fa­cil­i­ty to its Mid­west hub in RNAi drug pro­duc­tion push

4 years ago
Manufacturing

Cincin­nati plays host to new cell, vi­ral vec­tor man­u­fac­tur­ing site from Ex­pres­sion Ther­a­peu­tics

4 years ago
Manufacturing

End­points ed­i­tors se­lect the top trends of 2022: M&A looks hot as IPOs wane, it's time to see some hard da­ta on AI ...

4 years ago
Editor's note
Special
First page Previous page 604605606607608609610 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times